Eaton Vance Management raised its position in Illumina, Inc. (NASDAQ:ILMN) by 0.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 15,927 shares of the life sciences company’s stock after buying an additional 84 shares during the period. Eaton Vance Management’s holdings in Illumina were worth $2,764,000 at the end of the most recent reporting period.
Other hedge funds have also recently bought and sold shares of the company. Patriot Financial Group Insurance Agency LLC boosted its holdings in Illumina by 1.4% in the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 3,126 shares of the life sciences company’s stock worth $528,000 after buying an additional 43 shares during the last quarter. Paradigm Asset Management Co. LLC boosted its holdings in Illumina by 5.6% in the 2nd quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock worth $165,000 after buying an additional 50 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its holdings in Illumina by 298.7% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 10,447 shares of the life sciences company’s stock worth $1,813,000 after buying an additional 7,827 shares during the last quarter. Bank of Nova Scotia boosted its holdings in Illumina by 265.4% in the 1st quarter. Bank of Nova Scotia now owns 86,202 shares of the life sciences company’s stock worth $14,710,000 after buying an additional 62,612 shares during the last quarter. Finally, Eagle Asset Management Inc. acquired a new stake in Illumina in the 2nd quarter worth about $27,175,000. Institutional investors own 93.32% of the company’s stock.
In other Illumina news, Director Jay T. Flatley sold 20,000 shares of Illumina stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $178.21, for a total value of $3,564,200.00. Following the transaction, the director now owns 534,176 shares in the company, valued at approximately $95,195,504.96. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jay T. Flatley sold 22,540 shares of Illumina stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $195.21, for a total transaction of $4,400,033.40. Following the completion of the transaction, the director now owns 539,176 shares in the company, valued at approximately $105,252,546.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 195,434 shares of company stock worth $37,480,647. 1.60% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: This story was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.chaffeybreeze.com/2017/09/19/illumina-inc-ilmn-shares-bought-by-eaton-vance-management.html.
Shares of Illumina, Inc. (ILMN) opened at 209.40 on Tuesday. The stock has a market cap of $30.57 billion, a price-to-earnings ratio of 42.01 and a beta of 0.81. Illumina, Inc. has a 12 month low of $119.37 and a 12 month high of $214.34. The firm has a 50-day moving average price of $198.87 and a 200-day moving average price of $180.90.
Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.68 by $0.14. The company had revenue of $662.00 million for the quarter, compared to analyst estimates of $642.38 million. Illumina had a net margin of 30.27% and a return on equity of 19.69%. Illumina’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the business earned $0.86 EPS. Equities analysts expect that Illumina, Inc. will post $3.65 EPS for the current fiscal year.
ILMN has been the topic of several research analyst reports. Vetr upgraded Illumina from a “buy” rating to a “strong-buy” rating and set a $197.84 price objective on the stock in a report on Tuesday, May 23rd. BidaskClub upgraded Illumina from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Morgan Stanley reiterated an “underweight” rating and issued a $122.00 price objective (up from $115.00) on shares of Illumina in a report on Monday, July 10th. Barclays PLC reiterated a “hold” rating and issued a $150.00 price objective on shares of Illumina in a report on Wednesday, July 19th. Finally, Canaccord Genuity restated a “hold” rating and set a $170.00 target price on shares of Illumina in a report on Wednesday, July 26th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and ten have assigned a buy rating to the company’s stock. Illumina presently has an average rating of “Hold” and a consensus price target of $181.76.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.